Four companies have won spots on a potential 10-year, $159 million contract to provide preclinical drug development support services for the National Institute of Allergy and Infectious Diseases.
The multiple-award, indefinite-delivery/indefinite-quantity contract covers the development of manufacturing processes and analytical test procedures, regulatory services, manufacturing and product characterization in support of the development of biopharmaceutical drug candidates for infectious diseases, the National Institutes of Health said in a FedBizOpps notice.
The awardees are:
- Advanced Bioscience Laboratories
- CSRAâs Dynport Vaccine subsidiary
- Paragon Bioservices